At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 291 enrolled
Drug / intervention
LY3471851 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
In Brief
A Phase 2 clinical trial evaluating LY3471851 and Placebo for Systemic Lupus Erythematosus. Completed, enrolled 291 participants across 112 sites in 19 countries.
Detailed Summary
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesArgentina, Australia, Canada, Czechia, Germany, Hungary, India, Israel, Japan, Mexico, Poland, Puerto Rico, Romania, Russia, South Korea, Spain, Taiwan, Ukraine, United States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartAug 2020
Primary CompletionJan 2023
Study CompletionFeb 2023
TodayJul 2026
First PostedJun 16, 2020
Enrollment StartAug 19, 2020
Primary CompletionJan 10, 2023
Study CompletionFeb 16, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.0 years ago
Interventions
LY3471851drug
Administered SC
Placebodrug
Administered SC